<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045848</url>
  </required_header>
  <id_info>
    <org_study_id>Biofreedom V2.2</org_study_id>
    <nct_id>NCT03045848</nct_id>
  </id_info>
  <brief_title>Biofreedom Prospective Multicenter Observational Registry</brief_title>
  <official_title>Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of Biofreedom Stent in Patients With Coronary Artery Disease (Biofreedom Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wonju Severance Christian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LEADERS-FREE trial demonstrated the safety and efficacy of polymer-free drug-coated stent&#xD;
      (Biofreedom, Biosensors International Technologies, Singapore) in patients with high bleeding&#xD;
      risk. But, there are limited clinical evidences for extending these findings to generalized&#xD;
      patients who are eligible to PCI. Therefore, the purpose of this registry is to evaluate the&#xD;
      safety and efficacy of Biofreedom stent in patients with coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) and related interventional cardiology field are&#xD;
      rapidly growing in current era. First generation drug eluting stent (DES) needed long-term&#xD;
      dual antiplatelet therapy (DAPT) for preventing future stent thrombosis. But, second&#xD;
      generation DES showed better clinical outcomes in terms of target lesion revascularization&#xD;
      and stent thrombosis. Later, polymer technology that was used to release drugs gradually&#xD;
      improved. BASKET-PROVE II trial compared biodegradable polymer (BP) DES (Nobori, Terumo) with&#xD;
      durable polymer DES (Xience Prime, Abbott Vascular) and bare metal stent (ProKinetik,&#xD;
      Biotronik) for the safety and efficacy in 2-year follow-up. BP-DES showed 7.6% of event rates&#xD;
      in composite endpoint including cardiac death, myocardial infarction (MI), clinically&#xD;
      indicated target-vessel revascularization (TVR) which was non-inferior to DP-DES(6.8%) and&#xD;
      superior to bare metal stent (12.7%). There were no statistical differences for the event&#xD;
      rates of stent thrombosis, MI and cardiac death among three groups in 1-year follow-up.&#xD;
      Biodegradable polymer has begun to emerge and suggested the possibility of shortening the&#xD;
      duration of DAPT. LEEDERS-FREE trial was designed to confirm the safety and efficacy of&#xD;
      polymer-free drug-coated stent (Biofreedom, Biosensors International Technologies, Singapore)&#xD;
      compared to bare metal stent (Gazelle stent, Biosensors International Technologies,&#xD;
      Singapore) in patients with high bleeding risk. During 390 days, drug coated stent showed&#xD;
      significant superiority to bare metal stent for the safety composite endpoint (cardiac death,&#xD;
      MI or stent thrombosis) (9.4% vs. 12.9%, P=0.0005). Clinically-driven target-lesion&#xD;
      revascularization also showed significant differences between drug-coated stent (5.1%) and&#xD;
      bare metal stent (9.8%) (P&lt;0.001). This results provided new therapeutic options that DAPT&#xD;
      duration could be shortened to 1 month in patients with high bleeding risk. The rate of&#xD;
      cardiovascular events was relatively higher than second generation DES. However, this result&#xD;
      should be carefully interpreted because the main purpose of LEADERS-FREE trial is to enroll&#xD;
      high bleeding risk patients who are generally excluded in second generation DES studies.&#xD;
      Additional studies are needed because there are limited clinical evidences for extending&#xD;
      these findings of LEADERS-FREE trial to generalized patients who are eligible to PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Impossible device delivery because of sponsor change&#xD;
  </why_stopped>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Actual">November 10, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Device-oriented composite end point (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, any myocardial infarction not clearly attributable to a nontarget vessel, and clinically indicated target-lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite end point</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of any death, any myocardial infarction, and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction not clearly attributable to a non-target vessel</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target-lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target-vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">194</enrollment>
  <condition>Coronary Artery Disease Aggravated</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Biofreedom drug-coated stent</arm_group_label>
    <description>Subject implanted Biofreedom DCS for coronary artery disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biofreedom drug-coated stent</intervention_name>
    <description>BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.</description>
    <arm_group_label>Biofreedom drug-coated stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All-comers patient population with all subjects requiring coronary revascularization with a&#xD;
        drug-coated stent (DCS)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject with â‰¥ 19 years&#xD;
&#xD;
          -  Subject implanted with Biofreedom DCS within 1 month&#xD;
&#xD;
          -  Subject who decided to participation and signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known intolerance to heparin, aspirin, clopidogrel, biolimus, cobalt chromium or&#xD;
             contrast media (Subject with hypersensitivity to contrast media controlled by steroid&#xD;
             and pheniramine can be included this study, but subject with anaphylaxis to contrast&#xD;
             media will be excluded).&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Woman who have a plan of pregnancy during study period&#xD;
&#xD;
          -  Subject with life expectancy less than 12 months&#xD;
&#xD;
          -  Subject with cardiogenic shock&#xD;
&#xD;
          -  Subject treated with other drug-eluting stent (DES), bioresorbable vascular scaffold&#xD;
             (BVS) or bare metal stent (BMS)&#xD;
&#xD;
          -  Subject participating in other randomized controlled study with DES, BVS or BMS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junghan Yoon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <state>Chungcheongnam-do</state>
        <zip>31116</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon National University School of Medicine</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon-do</state>
        <zip>200-722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-do</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13495</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Busan</city>
        <state>Gyeongsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Health Service Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 29, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wonju Severance Christian Hospital</investigator_affiliation>
    <investigator_full_name>Junghan Yoon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Observational registry</keyword>
  <keyword>All-comers open label registry</keyword>
  <keyword>Drug coated stent</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Stenting</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

